Format

Send to

Choose Destination
MBio. 2014 Dec 30;6(1):e02304-14. doi: 10.1128/mBio.02304-14.

A 2-pyridone-amide inhibitor targets the glucose metabolism pathway of Chlamydia trachomatis.

Author information

1
Department of Molecular Biology, Umeå University, Umeå, Sweden Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå, Sweden Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, USA.
2
Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden Department of Chemistry, Umeå University, Umeå, Sweden.
3
Department of Molecular Genetics and Microbiology, Center for Microbial Pathogenesis, Duke University Medical Center, Durham, North Carolina, USA.
4
Department of Molecular Biology, Umeå University, Umeå, Sweden Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå, Sweden Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden.
5
Department of Molecular Biology, Umeå University, Umeå, Sweden.
6
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, California, USA.
7
Department of Molecular Microbiology and Center for Women's Infectious Disease Research, Washington University School of Medicine, St. Louis, Missouri, USA.
8
Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden Department of Chemistry, Umeå University, Umeå, Sweden Fredrik.almqvist@chem.umu.se Sven.bergstrom@molbiol.umu.se.
9
Department of Molecular Biology, Umeå University, Umeå, Sweden Laboratory for Molecular Infection Medicine Sweden (MIMS), Umeå University, Umeå, Sweden Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden Fredrik.almqvist@chem.umu.se Sven.bergstrom@molbiol.umu.se.

Abstract

In a screen for compounds that inhibit infectivity of the obligate intracellular pathogen Chlamydia trachomatis, we identified the 2-pyridone amide KSK120. A fluorescent KSK120 analogue was synthesized and observed to be associated with the C. trachomatis surface, suggesting that its target is bacterial. We isolated KSK120-resistant strains and determined that several resistance mutations are in genes that affect the uptake and use of glucose-6-phosphate (G-6P). Consistent with an effect on G-6P metabolism, treatment with KSK120 blocked glycogen accumulation. Interestingly, KSK120 did not affect Escherichia coli or the host cell. Thus, 2-pyridone amides may represent a class of drugs that can specifically inhibit C. trachomatis infection.

IMPORTANCE:

Chlamydia trachomatis is a bacterial pathogen of humans that causes a common sexually transmitted disease as well as eye infections. It grows only inside cells of its host organism, within a parasitophorous vacuole termed the inclusion. Little is known, however, about what bacterial components and processes are important for C. trachomatis cellular infectivity. Here, by using a visual screen for compounds that affect bacterial distribution within the chlamydial inclusion, we identified the inhibitor KSK120. As hypothesized, the altered bacterial distribution induced by KSK120 correlated with a block in C. trachomatis infectivity. Our data suggest that the compound targets the glucose-6-phosphate (G-6P) metabolism pathway of C. trachomatis, supporting previous indications that G-6P metabolism is critical for C. trachomatis infectivity. Thus, KSK120 may be a useful tool to study chlamydial glucose metabolism and has the potential to be used in the treatment of C. trachomatis infections.

PMID:
25550323
PMCID:
PMC4281921
DOI:
10.1128/mBio.02304-14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center